Atticus LLC v. FMC Technologies: Chlorantraniliprole Patent Suit Dismissed With Prejudice
Atticus, LLC filed a patent infringement action against FMC Technologies, Inc. in the North Carolina Eastern District Court, asserting four patents covering chlorantraniliprole-containing pesticide products. The plaintiff voluntarily dismissed all claims with prejudice under FRCP 41(a)(1)(A)(i) after 295 days — permanently closing the door on re-litigation of these specific claims.
Chlorantraniliprole Patent Clash Ends Before Trial as Atticus Walks Away
Atticus, LLC initiated this patent infringement action on 19 December 2024 in the U.S. District Court for the Eastern District of North Carolina, asserting four issued U.S. patents — US8530382B2, US9826737B2, US9332756B2, and US8709513B2 — against FMC Technologies, Inc. in connection with chlorantraniliprole-containing pesticide products. Chlorantraniliprole is an active ingredient in widely-used insecticides targeting diamide-resistant and other economically significant pest species, making the underlying patents commercially significant within the agrochemical sector.
After 295 days of litigation, Atticus voluntarily dismissed the entire action and all asserted claims with prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). A dismissal with prejudice constitutes a final adjudication on the merits as a matter of law, permanently barring Atticus from re-filing the same claims against FMC Technologies on the same patents. This represents a categorical end to the dispute between these parties on these specific IP rights.
The relatively swift resolution — under ten months from filing — suggests the parties may have reached a commercial accommodation, or that Atticus concluded litigation risk or cost did not justify continued pursuit, though the public record is silent on terms. No trial date, claim construction order, or substantive ruling appears in the docket prior to dismissal. The with-prejudice election is notable: it goes beyond what a mere settlement typically requires and may reflect a licensing resolution, FMC’s successful early pressure on claim validity or infringement, or an agreed commercial arrangement that rendered the suit moot.
Filing to Voluntary dismissal in 295 days
295 days from filing to dismissal — faster than the median U.S. district patent case resolution
Dismissed with prejudice: what the voluntary exit means for both parties
FRCP 41(a)(1)(A)(i): plaintiff’s right to dismiss, with a catch
Under Federal Rule of Civil Procedure 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order by filing a notice before the defendant serves an answer or a motion for summary judgment. Here, Atticus elected dismissal with prejudice — an unusual and consequential addition. While 41(a)(1) dismissals are typically without prejudice by default, a plaintiff may voluntarily choose with-prejudice terms, which operate as a final judgment on the merits and bar any future re-filing of the same claims.
Voluntary exit, permanent barAtticus forfeits the right to re-litigate these patent claims against FMC
By dismissing with prejudice, Atticus permanently relinquishes the ability to assert US8530382B2, US9826737B2, US9332756B2, and US8709513B2 against FMC Technologies in this or any future action on the same factual basis. This is a significant strategic concession. It may reflect a concluded licensing arrangement, a commercial settlement, or a judgment that the litigation economics did not support continuation — but none of these explanations are confirmed in the public record.
Claims extinguished as to FMCFMC Technologies achieves full legal closure on these four patents
FMC Technologies obtains the strongest possible outcome short of a court ruling in its favour: a with-prejudice dismissal that permanently insulates it from re-litigation by Atticus on these specific patents and products. FMC’s chlorantraniliprole product line faces no further exposure from this particular assertion. The outcome also avoids any public claim construction ruling that could have shaped how the asserted patents are interpreted in future disputes involving other defendants.
Full closure for FMCNo claim construction on record — patent scope remains untested publicly
Because the case resolved before any substantive ruling, the four asserted chlorantraniliprole patents remain unconstrued by any court in this dispute. Their scope is neither narrowed nor validated on the public record. For other agrochemical manufacturers active in the chlorantraniliprole space, this means the patents retain their full face value as enforcement tools. Third parties cannot rely on any judicial narrowing from this case when assessing their own freedom-to-operate exposure.
Patents unconstrued — FTO risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Atticus, LLC | Company | Agrochemical IP licensor — holder of US8530382B2, US9826737B2, US9332756B2, US8709513B2Search in Eureka ↗ |
| Defendant | FMC Technologies, Inc. | Company | FMC Technologies, Inc. — manufacturer and marketer of chlorantraniliprole-containing pesticide productsSearch in Eureka ↗ |
| Plaintiff counsel | Matthew J. Dowd | Attorney | Counsel for Atticus, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Robert J. Morris | Attorney | Counsel for Atticus, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Robert J. Scheffel | Attorney | Counsel for Atticus, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Dowd Scheffel PLLC | Law Firm | Representing Atticus, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP | Law Firm | Representing Atticus, LLCSearch in Eureka ↗ |
| Defendant counsel | David E. Bennett | Attorney | Counsel for FMC Technologies, Inc.Search in Eureka ↗ |
| Defendant counsel | Marc W. Vander Tuig | Attorney | Counsel for FMC Technologies, Inc.Search in Eureka ↗ |
| Defendant counsel | Sydney Kathleen Johnson | Attorney | Counsel for FMC Technologies, Inc.Search in Eureka ↗ |
| Defendant counsel | William Gabriel Pagan | Attorney | Counsel for FMC Technologies, Inc.Search in Eureka ↗ |
| Defendant law firm | Armstrong Teasdale LLP | Law Firm | Representing FMC Technologies, Inc.Search in Eureka ↗ |
| Defendant law firm | Coats & Bennett, PLLC | Law Firm | Representing FMC Technologies, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | North Carolina Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes FRCP 41(a)(1)(A)(i) and explicitly elects with-prejudice terms — a legally consequential choice that transforms a procedural exit into a final adjudication on the merits. No court order was required, and no judicial findings were made on infringement, validity, or claim scope. The with-prejudice designation means res judicata attaches: Atticus is permanently barred from asserting these claims against FMC Technologies on these patents. The absence of any motion practice or substantive ruling in the record leaves the commercial rationale for this election undisclosed.
US8530382B2, US9826737B2, US9332756B2 & US8709513B2 — Chlorantraniliprole Pesticide Formulations
The four asserted patents — US8530382B2, US9826737B2, US9332756B2, and US8709513B2 — cover compositions and methods relating to chlorantraniliprole, a diamide-class insecticide active ingredient widely used in crop protection. Chlorantraniliprole acts on ryanodine receptors in insect muscle cells, offering broad-spectrum control of lepidopteran and other pest species. The application dates span filings under both US12 and US13/14 series, suggesting a family of continuations developed over a period of active formulation research and patent prosecution.
Chlorantraniliprole is a high-value active ingredient with significant market share in row crop and specialty crop insecticides. Patent protection over formulations, methods of use, and compositions in this space is commercially sensitive, as generic and branded agrochemical companies compete aggressively on both regulatory approvals and IP exclusivity. For any manufacturer formulating or distributing chlorantraniliprole-based products without a licence from Atticus, these four patents represent a material infringement risk that warrants careful FTO assessment, particularly given that no claim construction record exists from this case to guide scope analysis.
Should you run an FTO against US8530382B2 and the Atticus chlorantraniliprole patent family?
Any agrochemical company — whether a generic manufacturer, branded formulator, or co-formulation partner — that produces, distributes, or sells chlorantraniliprole-containing pesticide products in the United States should treat this patent family as an active risk. The dismissal with prejudice in Atticus v. FMC Technologies produced no claim construction, no invalidity ruling, and no public narrowing of scope. The patents emerge from this case with their full enforcement potential intact.
PatSnap Eureka’s FTO Search Agent can map the claim landscape across all four Atticus patents, identify prior art relevant to validity challenges, and flag any continuation or divisional applications that may extend the family’s coverage. For R&D teams developing novel chlorantraniliprole formulations, Eureka can also run a targeted landscape search to identify design-around opportunities and assess whether proposed formulations fall within the claimed scope — reducing litigation exposure before product launch.
Run a freedom-to-operate analysis on US8530382B2 to assess your product’s exposure
Run FTO in Eureka →Similar Chlorantraniliprole & Agrochemical Patent Cases in U.S. District Courts
Explore related patent infringement actions involving chlorantraniliprole and agrochemical pesticide formulations filed in U.S. district courts, including comparable voluntary dismissal outcomes.
What this case signals for the agrochemical pesticide IP landscape
A four-patent chlorantraniliprole assertion ending in a with-prejudice dismissal carries distinct signals for agrochemical IP strategy and competitor risk.
With-prejudice voluntary dismissals often mask a concluded commercial deal
When a plaintiff elects dismissal with prejudice rather than without, it typically signals something beyond simple case abandonment. A licensing agreement, co-existence arrangement, or product market exit by one party are common drivers. IP and commercial teams in the agrochemical sector should monitor subsequent licensing disclosures or product line changes by either party for corroborating signals.
Four unconstrued patents remain live enforcement tools against other defendants
The dismissal resolves nothing about the patents’ validity or scope. US8530382B2, US9826737B2, US9332756B2, and US8709513B2 can still be asserted against any other party active in the chlorantraniliprole space. Manufacturers and formulators without a licence from Atticus should treat these patents as active risk vectors and conduct updated FTO analysis.
Atticus v FMC — key questions answered
Atticus, LLC asserted four U.S. patents: US8530382B2, US9826737B2, US9332756B2, and US8709513B2. All four relate to chlorantraniliprole-containing pesticide products. The case was filed on 19 December 2024 in the Eastern District of North Carolina and dismissed with prejudice by Atticus on 10 October 2025.
Dismissal with prejudice under FRCP 41(a)(1)(A)(i) means Atticus permanently relinquishes the right to re-file these patent infringement claims against FMC Technologies. It operates as a final adjudication on the merits, triggering res judicata. FMC cannot be sued again by Atticus on these four patents for the same accused products.
The public record does not confirm a settlement. The case was terminated by Atticus’s voluntary dismissal with prejudice. While a with-prejudice dismissal is consistent with a concluded licensing or commercial arrangement, no settlement terms, licence agreement, or monetary award are disclosed in the available docket materials.
The complaint identified chlorantraniliprole-containing pesticide products as the accused products. Chlorantraniliprole is a diamide-class insecticide active ingredient used in a range of crop protection formulations. FMC Technologies is a significant participant in the agrochemical market with established chlorantraniliprole-based product lines.
Yes. The dismissal with prejudice only bars Atticus from re-suing FMC Technologies on these patents. US8530382B2, US9826737B2, US9332756B2, and US8709513B2 remain enforceable against any other party. No claim construction or invalidity ruling was issued, so the patents’ scope is unchanged for enforcement purposes against third parties.
PatSnap Eureka searches patents and litigation data to answer instantly.